Is semaglutide legal in the United States?

Semaglutide is FDA-approved and prescription only, and this guide explains salt forms, compounding limits and FDA warning letters to research-labeled sellers, as of November 17, 2026.

Basics7 min read

Key takeaway

Semaglutide is FDA-approved and prescription only. The first semaglutide approval was Novo Nordisk’s Ozempic injection on December 5, 2017, followed by Rybelsus tablets in 2019 and Wegovy injection in 2021. FDA declared the semaglutide injection shortage resolved on February 21, 2025, and its temporary compounding allowances ended in May 2025. FDA says salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients with no known lawful basis for compounding. FDA has warned sellers of research-labeled semaglutide as recently as August 2026.

At a glance

Article typeBasics
Main guideWhat is semaglutide? Structure, research and FDA status
Regulatory statusFDA-approved“It is an FDA-approved prescription drug (Ozempic, Wegovy, Rybelsus)” (Where to buy semaglutide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited0 in this article · 29 across 14 articles on Semaglutide
ProductSemaglutide product page

Is semaglutide legal in the United States? Yes, as a prescription medicine. FDA has approved it as Ozempic, Rybelsus and Wegovy, in injection and tablet forms. The harder questions are about salt forms, compounding after the shortage ended, and semaglutide sold outside the prescription system. This guide takes them one at a time, using Drugs@FDA, DailyMed, FDA orders and warning letters checked on November 17, 2026.

Quick answer: Semaglutide is legal to prescribe and dispense as Ozempic, Rybelsus or Wegovy. Compounding is now limited. A 503A pharmacy may not regularly compound copies of the approved products, and semaglutide is on neither the 503B bulks list nor FDA’s shortage list. FDA treats semaglutide sold for human use outside an approved application as an unapproved new drug, and a “research use only” label has not changed that when marketing showed human use. Research-grade semaglutide is a laboratory reagent, not an alternative to a prescription medicine.

This article summarizes public regulatory records. It is not legal advice. For a decision about your own situation, ask a lawyer.

Is semaglutide FDA-approved?

Yes. Drugs@FDA lists these Novo Nordisk applications, each with marketing status “Prescription”:

  • Ozempic injection, NDA 209637, approved December 5, 2017 as a new molecular entity (Drugs@FDA);
  • Rybelsus tablets, NDA 213051, approved September 20, 2019; the same application now also lists Ozempic tablets (Drugs@FDA);
  • Wegovy injection, NDA 215256, approved June 4, 2021 (Drugs@FDA); and
  • Wegovy tablets, NDA 218316, whose first label is dated December 2025 (FDA label).

The current labels on DailyMed set out the approved uses. Ozempic injection (revised May 2026) is indicated to improve glycemic control in adults with type 2 diabetes, to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (DailyMed). Rybelsus and Ozempic tablets (revised January 2026) cover glycemic control and cardiovascular risk reduction in adults with type 2 diabetes (DailyMed). Wegovy (revised June 2026) is indicated, with diet and increased physical activity, for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and for weight reduction. The injection also has an accelerated approval for a form of liver disease called MASH with moderate to advanced fibrosis (DailyMed). For what the labels contain, see semaglutide and tirzepatide prescription labels. For costs, see semaglutide price.

What about semaglutide sodium and semaglutide acetate?

The approved drugs contain semaglutide base. FDA states that some compounders may sell salt forms, and that “these salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients” from the ones in approved drugs. FDA says it is “not aware of any lawful basis for their use in compounding” (FDA, 2026). In an October 2023 warning letter, FDA wrote that products containing these salts “have not been shown to be safe and effective” (FDA, 2023).

Can semaglutide still be compounded?

Only within narrow limits. Semaglutide injection products were added to FDA’s shortage list in March 2022 for Wegovy and August 2022 for Ozempic. In a declaratory order dated February 21, 2025, FDA “determined that the semaglutide injection product shortage is resolved” (FDA, 2025). After a court denied a preliminary injunction on April 24, 2025, FDA said the 503A wind-down period had ended; the 503B period ran to May 22, 2025 (FDA, 2026). On August 27, 2026, the Fifth Circuit affirmed the district court’s judgment in the compounders’ challenge (No. 25-10758).

FDA’s current policy, updated April 1, 2026, sets out what remains. A 503A pharmacy must compound for an individual patient on a prescription and may not compound essentially copies of a commercially available product “regularly or in inordinate amounts”; FDA does not intend to act on four or fewer such prescriptions in a calendar month. For 503B facilities, FDA wrote: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.” On April 30, 2026, FDA proposed not to include semaglutide on that list, finding “no clinical need” (FDA, 2026). Comments closed on July 30, 2026, and we found no final decision. Compounded drugs are not FDA-approved. See compounded semaglutide and the FDA and 503A vs 503B compounding.

Has FDA warned sellers of unapproved semaglutide?

Yes, many times. FDA says it has warned companies that sold unapproved semaglutide and similar products “falsely labeled” for research purposes or not for human consumption. Table 1 shows the letters and status checks we read.

Table 1

Semaglutide: approvals, FDA actions and status checks

Date What happened
December 5, 2017 FDA approves Ozempic injection (NDA 209637)
September 20, 2019 FDA approves Rybelsus tablets (NDA 213051)
June 4, 2021 FDA approves Wegovy injection (NDA 215256)
April 24, 2024 Warning letter to an online seller of unapproved, misbranded oral semaglutide products
December 10, 2024 Warning letter to a seller of semaglutide labeled “research use only”
February 21, 2025 FDA order: semaglutide injection shortage resolved
May 22, 2025 Last day of FDA’s 503B wind-down period
September 9, 2025 Warning letter over compounded semaglutide marketed as having the “same active ingredient” as Ozempic and Wegovy
March 3, 2026 FDA announces 30 warning letters to telehealth companies over compounded GLP-1 marketing
April 30, 2026 FDA proposes not to include semaglutide on the 503B bulks list
August 24, 2026 Warning letters to two sellers of research-labeled semaglutide
November 12, 2026 DEA controlled substances list edition; semaglutide not listed

The research-labeled cases follow one pattern. The December 2024 letter quoted “RESEARCH USE ONLY.” The February 2025 letter quoted “research use only” and “not for human consumption.” The August 2026 letters to Peptide Partners LLC and Tex Peptides quoted “not for human or veterinary use.” Each time, FDA wrote that evidence from the seller’s website established that the products were intended to be drugs for human use, and cited sections 505(a) and 301(d) of the Act. Our guide to FDA warning letters to peptide sellers lists each letter.

FDA also writes to online pharmacy websites that make no research claim at all. On September 23, 2026, it sent a warning letter to Online Generic Medicine/www.onlinegenericmedicine.com. On September 24, 2026, it sent one to Cheap Medicine Shop/www.cheapmedicineshop.com. FDA said it reviewed each website on August 26 and September 2, 2026, and that each introduced unapproved and misbranded injectable semaglutide products into interstate commerce. Each letter states that no approved application is in effect for the product it names, and cites sections 505(a), 301(d), 301(a), 502(f)(1) and 503(b)(1) of the Act. Both letters note that FDA-approved semaglutide products are available only by prescription. A warning letter states FDA’s view. It is not a court finding.

Is semaglutide a controlled substance?

Not under federal law. Semaglutide does not appear on the DEA’s alphabetical list of controlled substances, edition dated November 12, 2026 (DEA). That does not make a product lawful to sell as a drug. That question belongs to FDA.

What does research-use-only sale mean, and what are its limits?

A “research use only” label states the seller’s intended use: laboratory research, not use in people or animals. Research-grade semaglutide is a laboratory reagent. It is not Ozempic, Rybelsus or Wegovy, it is not made under an approved application, and it is not a substitute for a prescription medicine.

The label does not decide the legal question by itself. FDA judges intended use by “objective intent,” which may be shown by a seller’s expressions or “the circumstances surrounding the distribution of the article” (21 CFR 201.128). When the evidence shows a product is meant for people, FDA can treat it as an unapproved new drug despite the label.

Research-grade semaglutide in our catalog is sold for laboratory research use only, not for human or veterinary use. See also what research use only means.

Frequently asked questions about semaglutide legality

Is semaglutide FDA-approved?

Yes, as Ozempic, Rybelsus and Wegovy, in injection and tablet forms. All are prescription-only.

Can a pharmacy still compound semaglutide?

Only within limits. A 503A pharmacy may not regularly compound copies of the approved products. Semaglutide is on neither the 503B bulks list nor FDA’s shortage list.

Are semaglutide sodium and semaglutide acetate the same as semaglutide?

No. FDA says these salt forms are different active ingredients from the base form in the approved drugs, and it knows of no lawful basis for using them in compounding.

Does a “research use only” label make semaglutide legal to sell?

Not by itself. When website evidence showed human use, FDA treated research-labeled semaglutide as an unapproved new drug.

Is semaglutide a controlled substance?

No. It is not on the DEA’s federal list.

What to know now

  • FDA approval: Ozempic, Rybelsus and Wegovy, prescription only.
  • Salt forms: FDA says semaglutide sodium and acetate are different active ingredients.
  • Shortage: resolved February 21, 2025; wind-down periods ended by May 22, 2025.
  • 503B: not on the bulks list or the shortage list; FDA proposed leaving it off the list.
  • Enforcement: warning letters through August 2026 looked past research-use labels.
  • Research grade: for laboratory research use only, not for human or veterinary use.

What we’re watching

FDA’s final decision on its proposal to leave semaglutide off the 503B bulks list. New FDA warning letters to sellers of research-labeled or salt-form semaglutide. And further label changes for Ozempic, Rybelsus and Wegovy listed on Drugs@FDA.

Also in the library

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: U.S. Food and Drug Administration. Drugs@FDA: Ozempic (semaglutide) injection, Drugs@FDA: Ozempic (semaglutide) injection, NDA 209637; U.S. Food and Drug Administration. Drugs@FDA: Rybelsus and Ozempic (semaglutide) tablets, Drugs@FDA: Rybelsus and Ozempic (semaglutide) tablets, NDA 213051; U.S. Food and Drug Administration. Drugs@FDA: Wegovy (semaglutide) injection, Drugs@FDA: Wegovy (semaglutide) injection, NDA 215256; Novo Nordisk 2025, Wegovy (semaglutide) injection and tablets: Prescribing information; Novo Nordisk 2026, Ozempic (semaglutide) injection: Prescribing information; Novo Nordisk 2026, Rybelsus and Ozempic (semaglutide) tablets: Prescribing information; Novo Nordisk 2026, Wegovy (semaglutide) injection and tablets: Prescribing information; U.S. Food and Drug Administration 2026, FDA’s concerns with unapproved GLP-1 drugs used for weight loss; U.S. Food and Drug Administration 2023, Warning letter: www.semaspace.com, MARCS-CMS 665848; U.S. Food and Drug Administration 2025; U.S. Food and Drug Administration 2026, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize; United States Court of Appeals for the Fifth Circuit 2026, Outsourcing Facilities Association v. Food & Drug Administration; U.S. Food and Drug Administration 2026, FDA proposes to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list; Food and Drug Administration 2026, Federal Register, 91; U.S. Food and Drug Administration 2024, Warning letter: www.dashpct.com, MARCS-CMS 679727; U.S. Food and Drug Administration 2024, Warning letter: Summit Research Peptides, MARCS-CMS 695607; U.S. Food and Drug Administration 2025, Warning letter: USApeptide.com, MARCS-CMS 696885; U.S. Food and Drug Administration 2025, Warning letter: Hims & Hers Health, Inc. dba Hims, MARCS-CMS 716567; U.S. Food and Drug Administration 2026, FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s; U.S. Food and Drug Administration 2026, Warning letter: Peptide Partners LLC, MARCS-CMS 735063; U.S. Food and Drug Administration 2026, Warning letter: TXP Innovations LLC dba Tex Peptides, MARCS-CMS 735067; U.S. Drug Enforcement Administration 2026, Controlled substances: Alphabetical order; Code of Federal Regulations. 21 CFR 201.128: Meaning of “intended uses” . Legal Information Institute, 21 CFR 201.128: Meaning of “intended uses”; U.S. Food and Drug Administration 2026, Warning letter: Online Generic Medicine/www.onlinegenericmedicine.com, MARCS-CMS 737806. All 24 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. Drugs@FDA: Ozempic (semaglutide) injection, NDA 209637. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637
  2. U.S. Food and Drug Administration. Drugs@FDA: Rybelsus and Ozempic (semaglutide) tablets, NDA 213051. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051
  3. U.S. Food and Drug Administration. Drugs@FDA: Wegovy (semaglutide) injection, NDA 215256. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
  4. Novo Nordisk. (2025). Wegovy (semaglutide) injection and tablets: Prescribing information (NDA 218316, revised December 2025). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf
  5. Novo Nordisk. (2026). Ozempic (semaglutide) injection: Prescribing information (revised May 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  6. Novo Nordisk. (2026). Rybelsus and Ozempic (semaglutide) tablets: Prescribing information (revised January 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  7. Novo Nordisk. (2026). Wegovy (semaglutide) injection and tablets: Prescribing information (revised June 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  8. U.S. Food and Drug Administration. (2026). FDA’s concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  9. U.S. Food and Drug Administration. (2023, October 2). Warning letter: www.semaspace.com, MARCS-CMS 665848. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wwwsemaspacecom-665848-10022023
  10. U.S. Food and Drug Administration. (2025, February 21). Declaratory order: Resolution of shortages of semaglutide injection products (Ozempic and Wegovy). https://www.fda.gov/media/185526/download
  11. U.S. Food and Drug Administration. (2026). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of April 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  12. United States Court of Appeals for the Fifth Circuit. (2026, August 27; revised September 1, 2026). Outsourcing Facilities Association v. Food & Drug Administration, No. 25-10758. https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
  13. U.S. Food and Drug Administration. (2026, April 30). FDA proposes to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  14. Food and Drug Administration. (2026, June 26). List of bulk drug substances for which there is a clinical need under section 503B of the Federal Food, Drug, and Cosmetic Act; extension of comment period. Federal Register, 91, 38719. https://www.govinfo.gov/content/pkg/FR-2026-06-26/html/2026-12937.htm
  15. U.S. Food and Drug Administration. (2024, April 24). Warning letter: www.dashpct.com, MARCS-CMS 679727. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wwwdashpctcom-679727-04242024
  16. U.S. Food and Drug Administration. (2024, December 10). Warning letter: Summit Research Peptides, MARCS-CMS 695607. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024
  17. U.S. Food and Drug Administration. (2025, February 26). Warning letter: USApeptide.com, MARCS-CMS 696885. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usapeptidecom-696885-02262025
  18. U.S. Food and Drug Administration. (2025, September 9). Warning letter: Hims & Hers Health, Inc. dba Hims, MARCS-CMS 716567. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hims-716567-09092025
  19. U.S. Food and Drug Administration. (2026, March 3). FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
  20. U.S. Food and Drug Administration. (2026, August 24). Warning letter: Peptide Partners LLC, MARCS-CMS 735063. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026
  21. U.S. Food and Drug Administration. (2026, August 24). Warning letter: TXP Innovations LLC dba Tex Peptides, MARCS-CMS 735067. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/txp-innovations-llc-dba-tex-peptides-735067-08242026
  22. U.S. Drug Enforcement Administration, Diversion Control Division. (2026, November 12). Controlled substances: Alphabetical order. https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
  23. Code of Federal Regulations. 21 CFR 201.128: Meaning of “intended uses”. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/cfr/text/21/201.128
  24. U.S. Food and Drug Administration. (2026, September 23). Warning letter: Online Generic Medicine/www.onlinegenericmedicine.com, MARCS-CMS 737806. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/online-generic-medicinewwwonlinegenericmedicinecom-737806-09232026